These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 8959954

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy: a 14-year experience at a single institution.
    Suchin KR, Cucchiara AJ, Gottleib SL, Wolfe JT, DeNardo BJ, Macey WH, Bromley PG, Vittorio CC, Rook AH.
    Arch Dermatol; 2002 Aug; 138(8):1054-60. PubMed ID: 12164743
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma--the Düsseldorf and Munich experience.
    Prinz B, Behrens W, Hölzle E, Plewig G.
    Arch Dermatol Res; 1995 Aug; 287(7):621-6. PubMed ID: 8534123
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: a prospective controlled trial.
    Wollina U, Looks A, Meyer J, Knopf B, Koch HJ, Liebold K, Hipler UC.
    J Am Acad Dermatol; 2001 Feb; 44(2):253-60. PubMed ID: 11174383
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
    Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C.
    J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Extracorporeal photopheresis for the treatment of erythrodermic cutaneous T-cell lymphoma: a single center clinical experience with long-term follow-up data and a brief overview of the literature.
    Quaglino P, Knobler R, Fierro MT, Savoia P, Marra E, Fava P, Bernengo MG.
    Int J Dermatol; 2013 Nov; 52(11):1308-18. PubMed ID: 23786842
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The effect of extracorporeal photopheresis alone or in combination therapy on circulating CD4(+) Foxp3(+) CD25(-) T cells in patients with leukemic cutaneous T-cell lymphoma.
    Shiue LH, Couturier J, Lewis DE, Wei C, Ni X, Duvic M.
    Photodermatol Photoimmunol Photomed; 2015 Jul; 31(4):184-94. PubMed ID: 25772268
    [Abstract] [Full Text] [Related]

  • 17. Extracorporeal photopheresis and recombinant interferon alfa 2b in Sezary syndrome. Use of dual marker labeling to monitor therapeutic response.
    Vonderheid EC, Bigler RD, Greenberg AS, Neukum SJ, Micaily B.
    Am J Clin Oncol; 1994 Jun; 17(3):255-63. PubMed ID: 8192114
    [Abstract] [Full Text] [Related]

  • 18. Long-term follow-up and survival of cutaneous T-cell lymphoma patients treated with extracorporeal photopheresis.
    Knobler R, Duvic M, Querfeld C, Straus D, Horwitz S, Zain J, Foss F, Kuzel T, Campbell K, Geskin L.
    Photodermatol Photoimmunol Photomed; 2012 Oct; 28(5):250-7. PubMed ID: 22971190
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Role of extracorporeal photopheresis in the treatment of cutaneous T-cell lymphoma, autoimmune disease, and allograft rejection.
    Rook AH, Wolfe JT.
    J Clin Apher; 1994 Oct; 9(1):28-30. PubMed ID: 8195109
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.